179 related articles for article (PubMed ID: 36684904)
21. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
22. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
23. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
24. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
25. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.
Choi HCW; Jit M; Leung GM; Tsui KL; Wu JT
BMC Med; 2018 Aug; 16(1):127. PubMed ID: 30115065
[TBL] [Abstract][Full Text] [Related]
26. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
Joura EA; Garland SM; Paavonen J; Ferris DG; Perez G; Ault KA; Huh WK; Sings HL; James MK; Haupt RM;
BMJ; 2012 Mar; 344():e1401. PubMed ID: 22454089
[TBL] [Abstract][Full Text] [Related]
27. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
28. Cervical Cancer and Human Papillomavirus Awareness among Women in Antigua and Barbuda.
Honnavar P; Mansoor E; Tulloch C; Udayan U; Cosmello I; Patel P; Bersma A
Medicina (Kaunas); 2023 Jun; 59(7):. PubMed ID: 37512042
[No Abstract] [Full Text] [Related]
29. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
30. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study.
Man I; Georges D; de Carvalho TM; Ray Saraswati L; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Berkhof J; Sankaranarayanan R; Bogaards JA; Basu P; Baussano I
Lancet Oncol; 2022 Nov; 23(11):1419-1429. PubMed ID: 36174583
[TBL] [Abstract][Full Text] [Related]
31. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus-vaccinated and unvaccinated women: a population-based cohort study.
Krog L; Lycke KD; Kahlert J; Randrup TH; Jensen PT; Rositch AF; Hammer A
Am J Obstet Gynecol; 2024 Apr; 230(4):430.e1-430.e11. PubMed ID: 38569830
[TBL] [Abstract][Full Text] [Related]
32. A nationwide birth year-by-year analysis of effectiveness of HPV vaccine in Japan.
Yagi A; Ueda Y; Nakagawa S; Masuda T; Miyatake T; Ikeda S; Abe H; Hirai K; Sekine M; Miyagi E; Enomoto T; Nakayama T; Kimura T
Cancer Sci; 2021 Sep; 112(9):3691-3698. PubMed ID: 34252250
[TBL] [Abstract][Full Text] [Related]
33. Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models.
Reimers LL; Anderson WF; Rosenberg PS; Henson DE; Castle PE
Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):792-800. PubMed ID: 19258470
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
35. Declines in Human Papillomavirus (HPV)-Associated High-Grade Cervical Lesions After Introduction of HPV Vaccines in Connecticut, United States, 2008-2015.
Niccolai LM; Meek JI; Brackney M; Hadler JL; Sosa LE; Weinberger DM
Clin Infect Dis; 2017 Sep; 65(6):884-889. PubMed ID: 28520854
[TBL] [Abstract][Full Text] [Related]
36. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
Goldie SJ; Kohli M; Grima D; Weinstein MC; Wright TC; Bosch FX; Franco E
J Natl Cancer Inst; 2004 Apr; 96(8):604-15. PubMed ID: 15100338
[TBL] [Abstract][Full Text] [Related]
37. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
[TBL] [Abstract][Full Text] [Related]
38. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
39. Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012.
Hariri S; Markowitz LE; Bennett NM; Niccolai LM; Schafer S; Bloch K; Park IU; Scahill MW; Julian P; Abdullah N; Levine D; Whitney E; Unger ER; Steinau M; Bauer HM; Meek J; Hadler J; Sosa L; Powell SE; Johnson ML;
Emerg Infect Dis; 2015 Sep; 21(9):1557-61. PubMed ID: 26291379
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus-associated cancer incidence by disaggregated Asian American, Native Hawaiian, and other Pacific Islander ethnicity.
Shing JZ; Corbin J; Kreimer AR; Carvajal LJ; Taparra K; Shiels MS; Vo JB
JNCI Cancer Spectr; 2023 Mar; 7(2):. PubMed ID: 36790075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
